NPS Seeks Development Partners For Preos And Teduglutide, Reduces Force
This article was originally published in Pharmaceutical Approvals Monthly
NPS Pharmaceuticals is reducing its workforce and consolidating operations while continuing to advance two pipeline candidates - the osteoporosis agent Preos and the gastrointestinal treatment teduglutide -following a review of its financial situation
You may also be interested in...
New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.
Ocera Therapeutics is going against the tide of biologics for Crohn’s disease as its adsorptive carbon agent AST-120 enters Phase III in fistulizing Crohn’s disease.
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.